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Abstract
 
Autoreactive CD4
 
 
 
 T lymphocytes are critical to the induction of autoimmune disease, but
because of the degenerate nature of T cell receptor (TCR) activation such receptors also re-
spond to other ligands. Interaction of autoreactive T cells with other non–self-ligands has been
shown to activate and expand self-reactive cells and induce autoimmunity. To understand the
effect on the autoreactivity of naive cross-reactive T cells of activation with a potent nonself
ligand, we have generated a TCR transgenic mouse which expresses a TCR with a broad
cross-reactivity to a number of ligands including self-antigen. The activation of naive trans-
 
genic recombination activating gene (
 
Rag
 
)
 
2
 
 
 
/
 
 
 
 T cells with a potent non–self-ligand did not
result in a enhancement of reactivity to self, but made these T cells nonresponsive to the self-
ligand and anti-CD3, although they retained a degree of responsiveness to the non–self-ligand.
These desensitized cells had many characteristics of anergic T cells. Interleukin (IL)-2 produc-
tion was selectively reduced compared with interferon (IFN)-
 
 
 
. p21
 
ras
 
 activity was reduced and
p38 mitogen-activated protein kinase (MAPK) was relatively spared, consistent with known
biochemical characteristics of anergy. Surprisingly, calcium fluxes were also affected and the
anergic phenotype could not be reversed by exogenous IL-2. Therefore, activation with a hy-
perstimulating non–self-ligand changes functional specificity of an autoreactive T cell without
altering the TCR. This mechanism may preserve the useful reactivity of peripheral T cells to
foreign antigen while eliminating responses to self.
Key words: T lymphocyte anergy • autoimmunity • T cell cross-reactivity • superagonist • 
selective peripheral tolerance
 
Introduction
 
It is increasingly appreciated that the peripheral T cell rep-
ertoire of normal healthy humans and rodents is highly
cross-reactive and contains cells with the potential to
respond to a wide range of self-peptides presented by self-
MHC molecules (1, 2). This arises both because T lym-
phocyte survival in the thymus relies on activation by self-
peptides for positive selection (3), and because TCRs are
inherently cross-reactive, so the complete elimination of all
TCRs with the potential to respond to self would also sig-
nificantly compromise responses to pathogens (4). In many
models of organ-specific autoimmune diseases, the activa-
tion of these self-reactive T cells is sufficient to initiate a
delayed-type hypersensitivity (DTH)-like reaction directed
against the self-antigen in the target organ and resulting in
an autoimmune disease (5, 6). Understanding how cells
which have the potential to cross react with autoantigens
are regulated in the periphery, and how they become acti-
vated, is thus crucial to understanding the pathology of
these conditions.
Two mechanisms have been proposed to explain autore-
active T cell activation, bystander activation, and molecular
mimicry (7, 8). The first proposes the activation of autore-
active cells in the proinflammatory milieu engendered by
infection of the target tissue, and the second the cross-reac-
tive activation of autoreactive T cells by foreign peptide
mimics. In both these cases, it is held that because memory
cells have a lower activation threshold than naive T cells
(9), they may be more liable to cause disease upon reactiva-
tion with a foreign antigen. To investigate the question of
the potential of cross-reactive peptides of different poten-
cies (hierarchies) to influence the activation of an autoreac-
tive TCR, we have developed a TCR transgenic system
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using a receptor (the 1B6 TCR) with a hierarchy of re-
sponses to different peptide ligands, including the autoanti-
genic myelin proteolipid (PLP) peptide 139–151 (HSLGK-
WLGHPDKF; W144).
The 1B6 TCR was derived from a T cell clone which
was generated by immunization of a female SJL mouse
with the altered peptide Q144 (HSLGKQLGHPDKF) in
which glutamine (Q) has replaced the primary TCR con-
tact tryptophan (W) in the autoantigenic peptide (10). The
1B6 TCR is highly cross-reactive and is able to recognize a
number of other ligands with substitutions at position 144,
including the self-ligand W144, and the altered self-ligands
Y144 (HSLGKYLGHPDKF) and L144 (HSLGKLLGHP-
DKF) which stimulate cells much more strongly than other
ligands (see Table I). This finding raised the possibility that
activation with L144 would change the response of naive
1B6 cells to W144, making them more responsive to the
autoantigen. In contrast, we show in this paper that the ac-
tivation of naive 1B6 cells with the hyperstimulatory ligand
L144, compared with activation with Q144, leads to a re-
duction in all responses and particularly a loss of response to
activation with anti-CD3 and the autoantigen W144. We
found significant differences in the biochemical profiles of
the 1B6 T cells activated with the hyperstimulatory ligand
L144, in that these T cells showed many of the biochemical
hallmarks of anergic T cells.
 
Materials and Methods
 
Animals.
 
4–6-wk-old female SJL mice were purchased from
the The Jackson Laboratory and housed under specific pathogen-
free conditions. To generate the 1B6 TCR transgenic (Tg)
mouse, the TCRs AV1S, Ja10 and BV10S1A2, Db1, and Jb2.1
were cloned into shuttle vectors provided by Dr. M. Davis (Stan-
ford University, Palo Alto, CA) and the constructs coinjected
into the pronuclei of fertilized FVB oocytes. Seven founder lines
were generated, of which two have been maintained and crossed
onto the SJL genetic background. In these SJL transgenic mice, T
cell thymic selection was skewed into the CD4 single-positive
compartment (57 vs. 32% in littermate controls) with a reduced
selection into the CD8 single-positive compartment (3 vs. 11%).
This skewing is also seen in peripheral lymph nodes (CD4
 
 
 
: 74
vs. 68%; CD8
 
 
 
: 10 vs. 26%). The hierarchy of response to L144,
Y144, Q144, and W144 (see Fig. 1) was comparable to the pat-
tern seen with the 1B6 T cell clone (see Table I; reference 10).
All mice were maintained in accordance with the guidelines of
the Committee on Animals of Harvard Medical School, Boston.
 
Generation of the 1.16 Anti-1B6 TCR Antibody.
 
Balb/c mice
were immunized subcutaneously with a mixture of 
 
Rag2
 
 
 
/
 
 
 
 1B6
transgenic lymph node and spleen cells emulsified in complete
Freund’s adjuvant. They were boosted intravenously with 
 
Rag2
 
 
 
/
 
 
 
1B6 transgenic lymphocytes five times over the course of one
year and the spleen from the mouse with the highest anti-1B6 ti-
tre, as assessed by flow cytometry, was fused with myeloma cells
(SP2.0 cells; American Type Culture Collection CRL8006) 4 d
after the final boost, using polyethylene glycol 1450 and selection
in HAT medium. Supernatants from all viable fusants were
screened using a 1B6 T cell hybridoma and a control (9F8) T cell
hybridoma. Antibodies that were positive by FACS
 
®
 
 on 1B6 but
not 9F8 cells were cloned at least twice by limiting dilution. Fur-
 
ther screening was performed for specific growth inhibition of
1B6 T cell hybridoma and activation of 1B6 transgenic T cells.
Anti-1B6 antibodies stained 1B6 T cells, but not T cell clones ex-
pressing V
 
 
 
10 or V
 
 
 
1 paired with other TCR chains. The fusion
generated three clonotypic antibodies and one anti-V
 
 
 
10 anti-
body. One clonotypic antibody (1.16; an IgG1,
 
 
 
 isotype) was se-
lected for further expansion and used in analysis.
 
Antigens.
 
Peptide antigens with COOH-terminal amides
were synthesized by Quality Controlled Biochemicals. Most
peptides were 
 
 
 
90% pure, as determined by HPLC, and were
not purified further. The peptides used in these experiments were
variants of the native PLP 139–151 peptide W144 (HSLGK-
 
W
 
LGHPDKF), Q144 (HSLGK
 
Q
 
LGHPDKF), Y144 (HSLG-
K
 
Y
 
LGHPDKF) and L144 (HSLGK
 
L
 
LGHPDKF), and the
control peptide Neuraminidase 101–120 (EALVRQGLAKVAY-
VYKPNNT). The relative binding of the PLP analogue pep-
tides to I-A
 
s
 
 compared with W144 is 0.6 (Q144), 0.6 (Y144),
and 0.8 (L144).
 
Antibodies.
 
FACS
 
®
 
 staining for CD3, TCR, and CD4 was
performed with fluorochrome conjugated antibodies (BD Bio-
sciences). Analysis of cell death was performed using 7-AAD and
annexin-PE according to the manufacturer’s instructions (BD
Biosciences). Immunoprecipitations and Western blotting were
done with the following antibodies: biotinylated anti-CD3
 
 
 
,
anti–c-Jun NH
 
2
 
-terminal kinase (JNK; BD Biosciences), anti-
phosphotyrosine (4G10; Upstate Biotechnology), anti-phospho
p44,42 mitogen-activated protein kinase (MAPK),
 
*
 
 anti-phospho
p38 MAPK, anti-phospho JNK, anti-p44,42 MAPK, anti-p38
MAPK (Cell Signaling Technology), and anti-ZAP-70 (Santa
Cruz Biotechnology, Inc.). All secondary reagents were from
Jackson ImmunoResearch Laboratories.
 
Generation of T Cell Lines.
 
CD4
 
 
 
 lymph node cells (LNCs)
of 1B6 TCR Tg 
 
Rag2
 
 
 
/
 
 
 
 mice were sorted on a FACS
VantageSE™ (Becton Dickinson), yielding purities of 
 
 
 
99%.
Sorted CD4
 
 
 
 cells were cultured in 24-well plates (10
 
6
 
 cells/well)
with irradiated SJL splenocytes (10
 
7
 
 cells/well) and the indicated
concentrations of peptides in DMEM supplemented with 10%
heat-inactivated fetal bovine serum (BioWhittaker, Inc.), 0.1 mM
nonessential amino acids, sodium pyruvate (1 mM), 
 
l
 
-glutamine
(2 mM), MEM essential vitamin mixture (1
 
 
 
), penicillin (100
U/ml), streptomycin (100 U/ml), arginine (0.15 mM), aspar-
agine (0.1 mM), folic acid (0.1 mg/ml), and 2-mercaptoethanol
(5 
 
 
 
 10
 
 
 
5
 
 M; Sigma-Aldrich). From day 2 onwards, T cells were
expanded by feeding with culture medium supplemented with
0.6% T cell growth factor (T-Stim; Collaborative Biomedical
Research) and 0.06% recombinant IL-2. Cells were fed every
2–3 d and restimulated every 14 d by the appropriate antigen and
irradiated SJL spleen cells.
 
In Vitro Proliferation Assays and Cytokine Determinations.
 
T cells
(5 
 
 
 
 10
 
4
 
/well) were cultured in triplicate in 96-well round-bot-
tomed plates (Falcon) together with (a) irradiated SJL spleen cells
(5 
 
 
 
 10
 
5
 
/well) and the indicated concentrations of peptide or
anti-CD3 mAb, or (b) PMA plus ionomycin. After 48 h, [
 
3
 
H]thy-
midine (1 
 
 
 
Ci/well) was added for the last 16 h before harvesting
the cells. The incorporation of [
 
3
 
H]thymidine was determined in
a Beckman scintillation counter (Model LS 5000; Beckman
Coulter). Supernatants were collected after 40 h, diluted 1:2, and
cytokine concentrations were measured by specific capture ELISA
according to the manufacturer’s instructions (BD Biosciences).
 
*
 
Abbreviations used in this paper:
 
 AICD, activation-induced cell death;
LNC, lymph node cell; MAPK, mitogen-activated protein kinase; MCC,
moth cytochrome c. 
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Cell Stimulation for Biochemistry, Immunoprecipitation, and Immu-
noblot Analysis.
 
DAS cells (fibroblasts transfected with I-A
 
s
 
 and
expressing B7.1; a gift from Dr. S. Miller, Northwestern Uni-
versity, Evanston, IL) were taken as APCs for biochemical ex-
periments. They were pulsed with 100 
 
 
 
g/ml L144 peptide for
2 h at 37
 
 
 
C. All cells were kept in DMEM without supplements
on ice before activation. Two different modes of stimulation
were chosen: (a) T cells (2 
 
 
 
 10
 
7
 
/sample) were spun together
for 30 s at 4,000 rpm with 10
 
7
 
 peptide-pulsed DAS cells and
transferred immediately to 37
 
 
 
C or (b) biotinylated anti-CD3
 
 
 
(10 
 
 
 
g/ml) and avidin (25 
 
 
 
g/ml) were added to the T cell sus-
pension (2 
 
 
 
 10
 
7
 
/sample) and transferred immediately to 37
 
 
 
C.
The cells were lysed at the indicated time points in lysis buffer
(1% Brij96, 50 mM Tris, pH 7.6, 150 mM NaCl, 200 
 
 
 
M
PMSF, 10 
 
 
 
g/ml aprotinin, 10 
 
 
 
g/ml leupeptin, 10 mM NaF,
1 mM Na
 
3
 
VO
 
4
 
, and 10 mM Na
 
4
 
P
 
2
 
O
 
7
 
). Immunoprecipitations
of the lysates were done for 2 h at 4
 
 
 
C with the indicated mAbs
and 50 
 
 
 
l of Streptavidin-Agarose (Upstate Biotechnology) for
biotinylated anti-CD3
 
 
 
, or Protein A-Sepharose (Amersham
Biotech) for anti–ZAP-70. For the Western blots of kinases, ali-
quots of the cell lysates (corresponding to 2 
 
 
 
 10
 
6
 
 T cells) were
used. Proteins were electrophoresed in SDS-polyacrylamide
gels, transferred to Immobilon-P membranes (Millipore), and
visualized after Western blotting by the ECL detection system
(Amersham Biosciences).
 
Measurement Of Calcium Flux.
 
T cells (5 
 
 
 
 10
 
6
 
 cells/ml)
were incubated for 1 h at 37
 
 
 
C with 4 
 
 
 
g/ml Indo-1-AM (Mo-
lecular Probes) in HBSS/5% FCS. Dye-loaded cells were washed
twice and kept at RT for 30 min before use. For APC/peptide
stimulation, 10
 
6
 
 T cells were spun together for 30 s at 4,000 rpm
with 10
 
6
 
 peptide-pulsed I-A
 
s
 
 and B7 expressing fibroblast (DAS)
cells, gently resuspended, and immediately analyzed. For mAb
stimulation, biotinylated anti-CD3
 
 
 
 (10 
 
 
 
g/ml) and avidin (25
 
 
 
g/ml) were added to the T cell suspension (1.5 
 
 
 
 10
 
6
 
 cells/
sample). Calcium fluxes were read by determining the ratio of
410 nm/485 nm over time on a FACS VantageSE™ (Becton
Dickinson).
 
Determination of p21
 
ras
 
 Activity.
 
The activity of p21
 
ras
 
 was de-
termined by immunoprecipitating the active, GTP-bound form
of p21
 
ras
 
 with Raf1-Ras binding domain agarose beads and subse-
quent Western blotting with anti-p21
 
ras
 
 of the immunoprecipi-
tated proteins according to the manufacturer’s instructions (Up-
state Biotechnology).
 
Results
 
Generation and Characterization of the 1B6 TCR Transgenic
Mouse.
 
To investigate the effects of activating T cells with
different cross-reactive ligands we developed a TCR trans-
genic system using a previously well characterized T cell
clone (10; see Materials and Methods for details). The
Q1.1B6 T cell clone was generated from a female SJL
mouse (H-2
 
s
 
) immunized with the peptide Q144
(HSLGK
 
Q
 
LGHPDKF), which is an altered peptide ligand
of the native encephalitogenic autoantigenic peptide W144
(PLP 139–151; HSLGK
 
W
 
LGHPDKF). The TCR uses
V
 
 
 
1 and V
 
 
 
10. Detailed analysis of the clone, with pep-
tides with single amino acid substitutions at position 144,
allowed the characterization of a panel of APLs with equiv-
alent binding affinity to MHC class II, but a broad hierar-
chy in stimulatory potential for the 1B6 TCR (10). The
clone responded to both Q144, the self-antigen W144, and
the altered peptide Y144. For this clone the peptide L144
was identified as a superagonist ligand (10). It achieved
half-maximal proliferation at much lower antigen concen-
trations than Q144. At higher concentrations it induced the
secretion of proinflammatory cytokines not induced by the
agonist peptide Q144 (the phenotype of the Q1.1B6 clone
is summarized in Table I). This wide dose response gives us
the potential to investigate the phenotype of naive trans-
genic T cells exposed to varying strengths of stimulation
with cross-reactive ligands and determine the effects of this
cross-reactive activation and expansion on responses to an
autoantigen at the level of a single clonotype.
Using the TCR from the Q1.1B6 T cell clone, we gen-
erated a TCR transgenic mouse (the 1B6 mouse) which
was bred onto the SJL genetic background. The peripheral
CD4
 
 
 
 T cells of the 1B6 transgenic mouse recapitulate
the hierarchy of responses seen in the Q1.1B6 T cell
clone, in that the self-peptide W144 is a weaker ligand
and L144 is a superagonist ligand compared with the ago-
nist Q144 peptide (Fig. 1). As there is no commercially
available anti-TCR 
 
 
 
 or 
 
 
 
 chain monoclonal antibody for
this receptor, we also developed a clonotypic monoclonal
 
Table I.
 
Hierarchy of Response of the Q1.1B6 T Cell Clone to Various Ligands
 
Cytokine (pg/ml)
Ligand Sequence
Relative
MHC binding
Proliferative
response IFN-
 
  TNF-  IL-2 IL-4
L144 HSLGKLLGHPDKF 0.8      9,040 420 1,350 390
*Y144 HSLGKYLGHPDKF 0.6     N.D. N.D. N.D. N.D.
Q144 HSLGKQLGHPDKF 0.6    9,052  50  50 200
W144 HSLGKWLGHPDKF 1.0   420  50  50  50
Anti-TCR antibody – –    8,350  50  50 60
Data summarized from Nicholson et al. 1998 (reference 10) from a representative experiment, except *Y144 compiled from data obtained from 1B6
T cell hybridoma and 1B6 transgenic T cells. The Q1.1B6 T cell clone was derived from an SJL mouse immunized with Q144. L144 is a superagonist
ligand. Anti-TCR antibody activation is similar to activation with the cognate ligand Q144. N.D., not determined.1154 T Cell Desensitization
antibody for the 1B6 TCR. This allowed us to investigate
the behavior of this clone in vivo. This antibody was spe-
cific for the 1B6 receptor by the criteria that it stained and
activated 1B6 T cells, but did not stain T cell clones in
which V 1 or V 10 were paired with other TCR chains.
With these tools we examined functional T cell responses
of naive Rag2 /  1B6 T cells following activation with
cross-reactive ligands.
Loss of Responsiveness to Self-Ligands After Activation with
Nonself. We found that 1B6 T cells could be successfully
activated and maintained in culture with different ligands,
including Q144 and L144 over a wide range of peptide
concentrations. However, over time the phenotype of the
cells changed, in a manner which suggested a change in
the functional specificity of the T cell response. When the
functional responses of these cells were tested after 2 rounds
of activation in vitro, ( 30 d), we found that cells which
had been restimulated with 50  g/ml of Q144 or lower
concentrations (0.005  g/ml) of L144 responded briskly to
activation with all the ligands L144, Q144, or W144 (Fig. 2
A). We describe these as responsive cells. In contrast cells
which had been restimulated with 50  g/ml L144 had a
global impairment in their ability to proliferate. Their re-
sponse to L144 was reduced, while their response to the
autoantigen W144 and activation with anti-CD3 was com-
pletely abrogated. We describe these cells as desensitized
cells (Fig. 2 A). We found that activation in the presence of
IL-2 did not restore the responsiveness of the desensitized
cells (unpublished data). We reasoned that if these cells rep-
resented a population of transgenic 1B6 cells with nonspe-
cific defects in nuclear transcription, then they should also
be unresponsive to activation with PMA/ionomycin.
However, as shown in Fig. 2 B, desensitized cells retained
Figure 1. Phenotype of naive ex-vivo transgenic 1B6 T cells. The 1B6
TCR transgenic T cells retain the same hierarchy of response to peptide
ligands as the Q1.1B6 T cell clone. LNCs from a TCR transgenic mouse
were stimulated with different peptides and proliferation was assessed by
measuring the incorporation of [3H]thymidine added after 48 h of culture.
Figure 2. Culture with the superagonist peptide L144 affects the functional response of transgenic 1B6 T cells. Lymph node CD4  T cells from 1B6
TCR transgenic Rag2 /  mice were stimulated three times in vitro with 50  g/ml Q144, 50  g/ml L144, or 0.005  g/ml L144. 2 wk after the third
stimulation they were incubated with SJL/J splenocytes as APCs and the indicated concentrations of (A) L144, Q144, W144 peptides, or anti-CD3 and
APCs, or (B) PMA and ionomycin (c1   100 ng/ml PMA, 2  g/ml ionomycin; subsequent concentrations diluted 1:5) shown compared with activation
by anti-CD3 (c1   10  g/ml, subsequent concentrations diluted 1:5). Proliferation was assessed by pulsing the cultures with [3H]thymidine after 48 h.1155 Munder et al.
responsiveness to activation with PMA/ionomycin which
bypasses the proximal signaling machinery, arguing that
rather than developing a generalized defect of activation,
they had a proximal deficit in signaling.
When we compared the secretion of cytokines, the pro-
duction of IFN-  was similar between all the groups (Fig.
3). This suggests that the signaling pathways necessary for
the induction of IFN-  are equivalent between the differ-
ent groups of cells. In contrast, the secretion of IL-2 is se-
lectively blunted in the desensitized cells activated with
L144 and APCs (Fig. 3), although the desensitized cells do
retain the potential to secrete IL-2 when they are activated
with PMA/ionomycin (Fig. 3). When we analyzed the se-
cretion of the Th2 cytokines IL-4 and IL-10 in these ex-
periments there were no clear differences in the patterns of
secretion of these cytokines between groups (unpublished
data). Because superagonist peptide treatment in other
TCR transgenic systems has been associated with apoptosis
(11) and with receptor and coreceptor down-regulation
(12), we investigated if cell death and/or changes in the ex-
pression of the TCR was the mechanism responsible for
the phenotype of the desensitized 1B6 cells.
Activation-induced Cell Death and Receptor Down-Regulation
Is Normal in Superagonist-activated Transgenic 1B6 T Cells.
Despite complete unresponsiveness to stimulation with
anti-CD3, cells cultured with L144 at 50  g/ml were
healthy and proliferated vigorously on restimulation. We
wondered if activation of naive 1B6 T cells with L144 led
to massive apoptosis and the outgrowth of a minor subpop-
ulation of unresponsive T cells. To quantitate differences in
cell death on activation with different ligands, we analyzed
activation-induced cell death (AICD) directly by staining
annexin V and 7-AAD (Fig. 4 A). There was no evidence
of dramatically increased apoptosis, as there was no signifi-
cant increase in the frequency of annexin-positive CD4 
cells in the L144 (50  g/ml) activated cells, or in the fre-
quency of the annexin positive plus 7-AAD–positive cells
in this group, compared with the other groups. After the
first restimulation, viable rested T cells were present under
all activation conditions and, in fact, cells activated with
higher concentrations of L144 appeared to have expanded
better than cells activated with low concentrations of L144
or with Q144 (unpublished data). To determine whether
Figure 3. Selective loss of IL-2 but not IFN-  production from desen-
sitized 1B6 T cells. CD4  1B6 Rag2 /  T cells were cultured as described
in Fig. 1 and activated with L144 peptide and APC or with PMA/iono-
mycin. Supernatants were harvested after 40 h and analyzed for IL-2 and
IFN-  concentration by ELISA. Activation with antigen, but not PMA/
ionomycin fails to induce IL-2 secretion from the desensitized cells.
Figure 4. AICD and receptor/coreceptor expression are comparable.
(A) Naive CD4  1B6 Rag2 /  T cells were cultured with different anti-
gens for 48 h and then assessed for AICD by annexin and 7-AAD stain-
ing. The fraction of CD4  cells undergoing AICD was similar in all anti-
gen-treated groups. (B) CD4  1B6 Rag2 /  T cell lines were assessed for
expression of antigen receptor and CD4 before they were used in the assays
shown in Figs. 1 and 2. The level of receptor expression was equivalent in
the different populations.1156 T Cell Desensitization
the ability of 1B6 cells to survive activation with the super-
agonist was the consequence of receptor or coreceptor
down regulation, we examined the expression of TCR and
CD4 by flow cytometry immediately before restimulation.
As shown in Fig. 4 B there were no differences in the ex-
pression of these molecules on 1B6 T cells activated with
different ligands.
Taken together, this phenotype of normal TCR and
CD4 expression, with normal IFN-  secretion but defi-
cient IL-2 secretion, is characteristic of anergic T cells gen-
erated by suboptimal stimuli (e.g., by activation with fixed
APCs, plate bound anti-CD3, or weak agonists), but has
not been described after activation with a superagonist
ligand. However, although in vitro the 1B6 cells activated
with L144 expanded and were healthy, it was possible that
in vivo they would not be viable but would be deleted, as
has been described for another TCR transgenic cell acti-
vated with a superagonist ligand (11). To investigate this
possibility we studied transgenic 1B6 T cells which had
been transferred into naive SJL recipients using the clono-
typic antibody 1.16.
Immunization with Superagonist L144 Generates Desensi-
tized Cells In Vivo. To determine whether immunizing
SJL mice with L144 peptide compared with Q144 peptide
in CFA would have different effects on the functional phe-
notype of transgenic 1B6 T cells in vivo, we transferred
LNCs from naive 1B6 transgenic mice or littermate con-
trols into normal female SJL mice. 10 d after immunization
the recipient mice were killed and their LNCs were ana-
lyzed by flow cytometry and by proliferation assay (Fig. 5).
Flow cytometry showed that transgenic 1B6 cells were de-
tectable above background in Q144 and L144 immunized
mice and that there was an  3-4-fold greater expansion of
1.16-positive 1B6 cells in the lymph nodes of mice immu-
nized with L144 compared with mice immunized with
Q144 (Fig. 5 A). This demonstrated that activation in vivo
with L144 did not eliminate 1B6 T cells from the periph-
eral repertoire. Because we had immunized with L144 and
Q144 we could not formally distinguish the response of
1B6 cells from those of endogenous L144 or Q144 reactive
cells by performing a proliferation assay with these anti-
gens, although there is evidence that the transfer of anti-
gen-specific transgenic T cells can suppress the endogenous
T cell response (13). Therefore, to investigate the func-
tional phenotype of the 1B6 cells we determined how well
they responded both to L144 and Q144 and also to cross-
reactive peptides in vitro after immunization in vivo. Be-
cause of the well-characterized hierarchy of response of the
1B6 TCR, we could activate with several different peptides
specific for the 1B6 receptor, or with the clonotypic anti-
body 1.16. In agreement with the in vitro data, cells from
mice immunized with Q144 responded to all the ligands
tested and to the clonotypic antibody 1.16 (Fig. 5 B). In
contrast, mice immunized with L144, or mice that received
littermate nontransgenic LNCs, did not respond well to
Y144, or to activation with anti-1B6 1.16 antibody and
their responses to immunization with L144 or Q144 were
lower than the responses detected in mice which received
1B6 cells and were immunized (Fig. 5 B). This shows that
in vivo immunization with L144 can induce desensitized
cells within 10 d. All groups showed some response to
W144. We have previously described enhanced cross-reac-
tive responses to W144 after activation (14), which is due
to an expanded endogenous pool of W144-reactive cells
that is found in all I-As mice (15). Taken together, the in
vitro and in vivo data show that activation with hyperstim-
ulatory ligands expands the transgenic T cells but these ex-
panded cells are hyporesponsive to self-ligand (W144).
Based on our in vitro data, the unresponsiveness appeared
to be due to a proximal signaling defect rather than TCR
or CD4 down-regulation. To determine the mechanism of
this proximal signaling defect we analyzed the biochemical
phenotype of the desensitized 1B6 T cells.
p21ras, p44,42 MAPK, and JNK Activation Are Blocked in
Desensitized 1B6 T Cells. If activation with a superagonist
induces T cell anergy, then desensitized cells will have the
same biochemical characteristics as cells which have been
anergized conventionally. One of the fundamental blocks
in signal transduction upon TCR occupancy in anergic
cells lies at the level of p21ras (16, 17). This small GTPase is
Figure 5. 1B6 T cells are hyporesponsive but not deleted in vivo after
immunization with L144. Naive female SJL mice were reconstituted
with transgenic 1B6 T cells or LNCs from littermate controls and immu-
nized with L144 (50  g/ml) or Q144 (50  g/ml). 10 d after immuniza-
tion, LNCs were assessed for the number of surviving 1B6-clonotype–
positive CD4  cells by flow cytometry (A) and for their functional response
by proliferation (B). 1B6 T cells expanded well in mice immunized with
L144, but were hyporesponsive compared with cells obtained from mice
immunized with Q144 when they were tested in a proliferation assay ex
vivo.1157 Munder et al.
inactive when bound to GDP, but becomes activated when
GDP is exchanged for GTP. To analyze the activation sta-
tus of p21ras in desensitized and responsive cells, the GTP-
bound form of p21ras was immunoprecipitated with Raf-1
RBD beads and the amount of active p21ras in the immu-
noprecipitate was analyzed by Western blot. The responsive
cells show an activation-induced increase in GTP-bound
p21ras, which is already apparent 1 min after stimulation,
further increased at 3 min, and is still pronounced at 12 min
(Fig. 6 A). In comparison, the desensitized cells show only
a weak and retarded increase in the amount of active p21ras,
which was not apparent after 1 min but could be seen at
later time points.
The inability to activate p21ras is expected to lead to a
defect in activation of two of the three major mitogen-acti-
vated protein kinase (MAPK) pathways, p44,42 MAPK
and JNK, while in conventionally anergized cells, phos-
phorylation of the third major MAPK, p38 MAPK, is usu-
ally preserved. The activity of these MAPKs correlates with
their phosphorylation on threonines and tyrosines by up-
stream kinases. We therefore determined the inducibility of
the three MAPK pathways in the desensitized T cells by us-
ing phosphorylation state–specific antibodies. Upon cross-
linking of CD3 the activation of p44,42 MAPK and JNK is
severely reduced in the desensitized cells compared with
the control responsive cells (Fig. 6 B). When we analyzed
the third MAPK pathway in desensitized cells, we found
that the phosphorylation of p38 MAPK, although slightly
diminished, was relatively spared compared to that of
p44,42 MAPK and JNK, suggesting that this phenotype is
the result of a specific and selective inhibition of T cell ac-
tivation. To assess this further we analyzed the status of cal-
cium flux in desensitized cells.
The Sustained Calcium Flux Is Impaired in the Desensitized
Cells. Signaling via calcium influx is a major pathway that
is stimulated after TCR occupancy and is spared in most
models of anergy, but has been shown to be exclusively af-
fected in some models of anergic human T cells (18). Prox-
imal phosphorylation events lead to the activation of phos-
pholipase C 1 (PLC 1) and the subsequent production of
inositol-1,4,5-trisphosphate (IP3), the release of calcium
from intracellular stores, and the calcium-triggered influx
of extracellular calcium (19). To study the signal transduc-
tion via calcium in the desensitized cells, we labeled these
cells and the responsive cells with the calcium binding dye
Indo-1-AM, stimulated them with anti-CD3 or with APCs
and peptide, and analyzed the resulting increase in calcium
concentration by flow cytometry (20). Bypassing upstream
signaling events by stimulation with the calcium ionophore
ionomycin induced equivalent calcium fluxes in both cell
types; however, activation through the antigen receptor led
to patterns of calcium flux which were strikingly different
in the two cell types (Fig. 7). Whereas the initial Ca2  peak
was comparable in the two cell populations, the sustained
plateau in free cytosolic calcium concentration ([Ca2 ]i),
that is apparent in the responsive T cell population, is com-
pletely absent in the desensitized cells. This pattern is seen
upon anti-CD3 stimulation and with all the tested concen-
trations of the peptide L144 presented by APCs. The
amount of fluxing relative to stimulation with ionomycin is
reduced by an average of 55% in the desensitized cells un-
der all activating conditions (Fig. 7). The phenotype of cal-
cium flux in the desensitized cells cannot be reproduced in
normally responsive cells by lowering the antigen concen-
tration of the stimulating peptide, demonstrating again that
the desensitized cells are fundamentally different from the
normally responsive cells in terms of their calcium flux.
Therefore, although bypassing proximal signaling with
PMA/ionomycin or activation with the superagonist L144
can activate desensitized cells as well as the responsive cells,
they have pronounced impairment of both the calcium sig-
naling pathways as well as downstream MAPK signaling
pathways (p44,42 MAPK, JNK, but not p38 MAPK).
TCR-induced Phosphorylation of TCR , CD3 , and ZAP-
70 Is Impaired in the Desensitized Cells. Stimulation of T
cells with suboptimal variant ligands has been associated
with various changes in the proximal tyrosine phosphory-
lation patterns. Normally upon stimulation of a T cell via
Figure 6. Impaired activity of p21ras, p44,42 MAPK, and JNK in the
desensitized cells. (A) T cells of the responsive (cultured with L144 0.005
 g/ml) and desensitized (cultured with L144 50  g/ml) cell lines were
stimulated by cross-linking anti-CD3. At the indicated time points the
cells were lysed and the active, GTP-bound form of p21ras was immuno-
precipitated with Raf-1 RBD agarose beads. The immunoprecipitated
proteins were analyzed by SDS-PAGE and Western blot for p21ras. As a
control for equal content of total p21ras protein in the different samples
before immunoprecipitation, an aliquot of the cell lysate (corresponding
to 2   106 cells) was separately analyzed by Western blot for p21ras (bottom
half of the panel). (B) T cells from the responsive and desensitized cell
lines were stimulated by cross-linking anti-CD3 as described for panel A.
At the indicated time points the cells were lysed and aliquots of the cell
lysates (corresponding to 2   106 cells) were analyzed by SDS-PAGE and
Western blot with phosphorylation-state–specific mAbs for the phosphor-
ylated forms of p44,42 MAPK, JNK, and p38 MAPK. To control for
equal loading, parallel Western Blots with mAbs for each kinase are
shown below the respective blots for the phospho-form.1158 T Cell Desensitization
the TCR by anti-CD3 or cognate peptide plus APC,
ITAMs of the TCR  and TCR   chains become phosphor-
ylated via Src family kinases. The Syk family kinase ZAP-
70 binds to phosphorylated ITAM motifs and is itself phos-
phorylated and activated by Src kinases. ZAP-70/Syk
family PTKs are then thought to induce tyrosine phos-
phorylation of important downstream targets including
LAT, SLP-76, and PLC 1 (21). Anergy induced by activa-
tion with fixed APCs has been reported to induce near
normal patterns of TCR  and ZAP-70 tyrosine phosphor-
ylation (22), while anergy induced with APLs has been
shown to be associated with changes in the ratio of p21/
p23 TCR  (23). It was therefore important to investigate
the possibility of a very proximal impairment or block in
the TCR signal transduction within the desensitized cells,
and determine whether activation with the superagonist
L144 induced normal patterns of tyrosine phophorylation.
We stimulated desensitized cells with APCs and peptide,
immunoprecipitated the CD3 complex at various time
points after activation, and determined the extent of tyro-
sine phosphorylation of both the CD3  chains and the
coimmunoprecipitated TCR  chains (Fig. 8 A). As ex-
pected, both the responsive and desensitized cells showed
slight constitutive tyrosine phosphorylation of the TCR 
chain, demonstrated by the detection of the p21 phospho-
form of TCR  before stimulation. This form of TCR  is
associated with nonphosphorylated, inactive ZAP-70 ki-
nase (24). Upon TCR-mediated stimulation a pronounced
increase in TCR p21 is detectable in the responsive cells.
Additionally, the appearance of the p23 form of TCR 
signals the presence of fully phosphorylated TCR  chain
ITAMs, a prerequisite for phosphorylation and activation
of ZAP-70 (23, 25, 26). In comparison, the desensitized
cells show a drastically reduced phosphorylation of TCR 
chains. The p21 phospho-form is briefly enhanced but re-
turns to baseline at 12 min and there is only weak induc-
tion of the p23 form. The ratio of p23/p21, which is a
critical indicator of the degree of proximal T cell activation
(23, 25), is at least twofold higher in the responsive cells
than in the desensitized cells (Fig. 8 A). Overall, the induc-
tion of TCR  phosphorylation in the desensitized cells is
retarded, weaker, and terminated earlier compared with
the responsive cells. Similarly striking is the absence of an
increase in phosphorylation of the CD3  chain in the de-
sensitized cells compared with the pronounced induction
of phosphorylation in the control cells.
Finally, we looked for the activation-induced association
of phosphorylated ZAP-70 with the CD3 complex/TCR 
chain in both cell lines. When the responsive cells were
stimulated with anti-CD3 or L144 plus APC, a phospho-
band of  70 kD was apparent in the anti-phosphotyrosine
Western blots of the CD3  immunoprecipitations (unpub-
lished data), whereas there was no detectable band in the
case of the desensitized cells. To confirm that ZAP-70
phosphorylation was absent or diminished in the desensi-
tized cells, we immunoprecipitated ZAP-70 at various time
points following stimulation and tested in anti-phosphoty-
rosine Western blots. Again a pronounced activation-induced
phosphorylation of ZAP-70 was notable in the responsive
cells. By means of direct immunoprecipitation of ZAP-70
we were able to pick up a slight phosphorylation of the ki-
nase even in the desensitized cells, but the difference be-
tween the two cell lines remains striking (Fig. 8 B). Strip-
ping and reprobing the blot with anti-ZAP70 confirmed
comparable amounts of unphosphorylated protein at all
time points (Fig. 8 B).
Discussion
The 1B6 TCR transgenic mouse provides a novel op-
portunity to investigate the response of T cells to self-anti-
gen, after encounter with cross-reactive ligands. We show
in this paper that when T cells are exposed to superagonist
ligands they become desensitized, lose responses to self-
peptides and to anti-CD3, but still retain the ability to re-
spond to the superagonist ligand. In this system superago-
Figure 7. Impairment in sustained
calcium influx in the desensitized
cells. T cells of the responsive and
desensitized cell lines were loaded
with the indicator dye Indo-1-AM.
Calcium mobilization of the cells
was monitored continuously by flow
cytometry upon stimulation of the T
cells with ionomycin, cross-linking
anti-CD3, or with I-As/B7 express-
ing DAS cells, that had been loaded
with the indicated concentrations of
L144 peptide (start of stimulation in-
dicated by arrow). Calcium mobili-
zation in antibody and antigen stim-
ulated cells was measured and
compared with activation with ion-
omycin, by comparing the number
of gated events above a baseline in
the total time after stimulation (con-
verted to arbitrary units and taking
flux induced with ionomycin as 1.0).1159 Munder et al.
nist-activated cells are viable in vitro and in vivo, and ex-
press TCR at the same level as cells activated by weaker
stimuli, but surprisingly the phenotype of these desensitized
cells is very similar to that reported for cells that have been
anergized by activation with suboptimal stimulation. This
contrasts with experiments that show that activation in vivo
with superagonist peptides can lead to peripheral T cell de-
letion (11), a point that emphasizes that the results in this
system reflect part of a spectrum of possible responses to T
cell activation.
It is not certain from these experiments whether the state
which is induced is the result of the induction of specific
anergy inducing proteins in all cells, or the selection of cer-
tain cells from the whole population of T cells, and there-
fore we cannot come to a definitive conclusion as to
whether we are dealing with instruction or selection. As
with experiments to address this same question in studies of
differentiation to a Th1 or Th2 phenotype, this is a difficult
question to answer. The majority of all activated T cells
undergo AICD, and selection of one population over an-
other is argued to be a major mechanism for achieving T
cell differentiation (27). We have not observed a major
“crash” of L144 activated cells compared with Q144 acti-
vated cells over the duration of the experiments reported in
this paper and if selection of a sub-population of cells
which is already anergic is critical for survival after activa-
tion with L144 peptide, then this subpopulation must be a
large fraction of the CD4 cells that survive AICD in vitro
after activation with L144.
It is clear that although globally desensitized, these cells
retain a brisk response to L144 at nM concentrations of
peptide, but lose responsiveness to the autoantigen W144,
a change in functional specificity that could be significant
in autoimmune disease. That the mechanism is specific and
not a global hyporesponsiveness is argued by the data
showing that downstream responses induced by PMA/ion-
omycin are retained, and by the specific defect in IL-2 but
not IFN-  secretion. In addition, the changes in signaling
biochemistry indicate a specific block in activation affecting
p21ras, as has been described in other models of anergy.
The desensitization induced by the superagonist peptide
has various interesting aspects, which may distinguish it
from previously known types of anergy. T cell anergy is
generally assumed to result from partial T cell activation
(18). Examples of this type of anergy induction are TCR
stimulation without costimulation, either by fixed APCs
with agonist peptides (28), by live APCs with suboptimal
ligands (29), or by cross-linking the TCR with antibody
alone (30). In human T cells anergy has also been induced
by expanding T cells in the presence of large doses of IL-
10 and antigen (31). Two different biochemical mecha-
nisms have been identified in anergic cells: in the classical
models of anergy there is defective p21ras activation
(16,17), whereas in human T cells, anergy has sometimes
been attributed to defective calcium fluxes (18). In addi-
tion to these mechanisms, anergy induced by partial ago-
nists has been shown to be associated with incomplete
CD3  chain and ZAP-70 phosphorylation (23, 25). Sev-
eral in vivo models of anergy have confirmed these find-
ings (32, 33) or pointed to defects in calcium signaling
(34–36) in anergic cells.
When we examined the proximal CD3 associated signal-
ing pathways induced by L144, we found that the superag-
onist peptide L144 induces a fully agonistic pattern of
TCR  chain tyrosine phosphorylation in naive 1B6 TCR
transgenic cells (unpublished data). However, after activa-
tion with the hyperstimulating peptide L144, this pattern
changes dramatically. Stimulation with the same peptide
now produces a TCR  phosphorylation pattern (Fig. 8 A)
which recapitulates the findings originally described in a T
cell clone stimulated with an anergy-inducing APL (23).
Although Sloan-Lancaster et al. (23) reported sustained
phosphorylation of the CD3  chain for at least 20 min
upon agonist stimulation, in our experimental system the
p21 and p23 forms of CD3  decrease earlier in both cell
lines (Fig. 8). It is difficult to judge if this reflects subopti-
mal stimulation even in the responsive Q144 cell line as the
systems differ with regard to the antigen, the cell type
(short term T cell line as opposed to established T cell
clones), and the mode of stimulation. Similar to our obser-
vation, in newly generated AND TCR transgenic T cell
lines,   chain phosphorylation upon stimulation with the
high-affinity ligand moth cytochrome c (MCC) is already
Figure 8. Impaired tyrosine phosphorylation of TCR , CD3 , and
ZAP-70 in desensitized cells. (A) T cells of the responsive and desensitized
cell lines (2   107 cells for each time point) were stimulated with I-As/
B7 expressing DAS cells (loaded with 100  g/ml of L144 peptide) as
APCs. At the indicated times, the cells were lysed and the lysates subjected
to immunoprecipitation with anti-CD3  mAb. The immunoprecipitated
proteins were analyzed by Western blot with an anti-phosphotyrosine–
specific mAb. The relative ratio of p23 and p21 were measured as indi-
cated by image analysis using the Scion Image package. We were unable
to determine the total loading of CD3  by stripping and reprobing. (B)
The responsive and tolerant cells were activated with L144 peptide and I-
As/B7 expressing DAS cells. After lysis and immunoprecipitation with
anti-ZAP-70 antibody, Western blotting with anti-phosphotyrosine-spe-
cific mAb was performed and showed reduced ZAP-70 phosphorylation
in the desensitized cells. After stripping the blot was reprobed with anti-
ZAP-70 to control for loading.1160 T Cell Desensitization
terminated at 15 min (37). In our view it is therefore only
safe to deduce that within our system the responsive and
the desensitized cells clearly differ in their pattern of proxi-
mal tyrosine phosphorylation, most notably in the ratio of
p21/p23. The desensitized cells also show defective activa-
tion of the p21ras pathway, and they also have abnormal
patterns of calcium mobilization, with a reduction in sus-
tained calcium influx after activation. Sustained elevation
of intracellular Ca2 , which is required for efficient tran-
scription of the IL-2 gene (19, 38, 39), requires the influx
of extracellular calcium through activated calcium chan-
nels, and this may be uncoupled in the desensitized cells in-
duced by activation with L144 peptide. The calcium phe-
notype of the desensitized cells in this regard resembles that
of Itk /  cells (40). Induction of selective unresponsiveness
toward lower-affinity ligands has recently been analyzed in
AND TCR transgenic cells (37). Compared with a trans-
genic Th1 cell population, the Th2 cells fail to recruit
TCR complex members to lipid rafts, which seems to ac-
count for their impaired signaling capacity. It remains to be
elucidated if a similar difference in membrane micro-
domain partitioning is operative in our system of superago-
nist-induced unresponsiveness.
The novel type of superagonist-induced anergy we de-
scribe here is clearly not the consequence of partial activa-
tion of the T cells. Furthermore, it seems to involve the
p44,42 and JNK MAPK signaling pathways and signaling
via calcium, which are simultaneously severely impaired.
This biochemical phenotype points to a profound block in
activation. This is also reflected in the fact that exogenous
IL-2 is not able to rescue the anergic cells. This is in con-
trast to conventional anergy which can be reversed by cul-
turing the anergic cells in IL-2 containing medium (41).
However, this feature of superagonist-induced anergy is
not unique, in that IL-2 cannot reverse anergy in a murine
model system of partial agonist-induced anergy (42) and in
IL-10–induced anergy in human T cells (31). Taken to-
gether, it is clear that anergy is not one unique entity,
rather, different modes of induction seem to induce differ-
ent degrees of anergy (18). Superagonist-induced anergy
occupies a space at the very refractory end of this spectrum.
This description of desensitization of peripheral T cells is
clearly reminiscent of findings described in thymic selection
in vivo in a V 2/V 8.1 transgenic mouse (43). The TCR
these mice express is specific for a lymphocytic choriomen-
ingitis virus (LCMV) peptide, and due to the V 8.1 TCR
chain usage also possesses potential reactivity toward Mls-
1a and staphylococcal enterotoxin B (SEB). When Mls-1a
was introduced into these mice during thymic selection it
resulted in CD8  T cells that lost reactivity selectively to
Mls-1a, while cells with normal reactivity toward the
LCMV peptide and the superantigen SEB were retained.
The authors concluded from these data that thymocytes
rendered tolerant of low-affinity self-antigen can develop
into T cells which retain responsiveness for high-affinity
foreign antigens. Similar divergent changes in reactivity to-
ward weak and strong agonists have been noted in other
models of thymic differentiation (44, 45), in which devel-
oping thymocytes maintain reactivity to strong agonists,
while simultaneously losing reactivity to weak agonists. It
was recently reported in a double transgenic model with
TCR specificity for MCC and transgenic expression of the
antigen, that peripheral T cells in these mice are hypopro-
liferative toward MCC while retaining their reactivity to-
ward the superantigen SEA (46). The authors could show
in this experimental system that the anergic T cells had es-
caped negative selection in the thymus by expressing en-
dogenous  -chains and that they behaved essentially as low
avidity naive cells in the periphery. We could rule out the
possibility that our in vitro culture conditions selected for
such double  -chain expressing cells by using T cell lines
derived from Rag2 /  mice, in which all T cells express
only the 1B6 transgenic    TCR.
We speculate that these changes in functional specificity
may be useful in the context of a normal immune response
in that they preserve useful reactivity to a foreign specificity
but reduce reactivity with self. Such a scenario leads to an
increase in specificity at the expense of sensitivity, which is
clearly a viable trade off in terms of the responses to L144
which occur over such a wide dose response. Our observa-
tions fit into the concept of flexible T cell activation
thresholds, that can be tuned upon activation of the TCR
with stimuli of different strengths (12, 47, 48). This paper
presents experimental evidence for such a flexible threshold
and changes in the reactivity of a T cell after activation
with a cross-reactive ligand. Indeed in these circumstances,
the functional specificity of the T cell changes without
changing the level of expression or the specificity of the
TCR. This may be of particular interest in studies of au-
toimmune disease where infection is widely regarded as an
important precipitating factor for induction of autoimmune
disease; our experiments provide an example of how in
some circumstances infection may induce peripheral toler-
ance by reducing responsiveness to autoantigen. Thus, we
have described a novel mechanism by which a cross-reac-
tive TCR may retain functional responses to nonself but
lose responses to self-ligand without deleting the clonotype
from the peripheral repertoire.
The authors would like to thank R. Nazareno for maintaining and
screening mice, B. Rich and J. Murphy who provided Rag2 / 
mice for breeding, and N. Price who provided technical assistance.
We would also like to thank R. McGilp for help with analysis of
calcium flux, and Edward Greenfield for performing the fusion that
produced the 1.16 antibody. 
M. Munder was supported by grant Mu1547/1-1 of the Deutsche
Forschungsgemeinschaft. This work was also supported by grants
from the National Institutes of Health (K08 AI01557-01) and
the National Multiple Sclerosis Society, New York (RG3257) to
L.B. Nicholson and from the National Institutes of Health
(R01NS30843, R01NS35685, P01AI39671-01A1, PO1NS38037-
01A1), and the National Multiple Sclerosis Society (NMSS), New
York (RG2571, RG2320) to V.K. Kuchroo. J.M. Slavik is a fellow
of the NMSS.
Submitted: 12 March 2002
Revised: 13 August 2002
Accepted: 13 September 20021161 Munder et al.
References
1. Kersh, G.J., and P.M. Allen. 1996. Essential flexibility in the
T-cell antigen recognition of antigen. Nature. 380:495–498.
2. Mason, D. 1998. A very high level of crossreactivity is an es-
sential feature of the T-cell receptor. Immunol. Today. 19:
395–404.
3. Bevan, M.J. 1997. In thymic selection, peptide diversity gives
and takes away. Immunity. 7:175–178.
4. Goldrath, A.W., and M.J. Bevan. 1999. Selecting and main-
taining a diverse T-cell repertoire. Nature. 402:255–262.
5. Zamvil, S.S., and L. Steinman. 1990. The T lymphocyte in
experimental allergic encephalomyelitis. Annu. Rev. Immunol.
8:579–621.
6. Kuchroo, V.K., N. Sarvetnick, D.A. Hafler, and L.B.
Nicholson. 2002. Cytokine and Autoimmune Diseases. Hu-
mana Press, Totowa, New Jersey.
7. Vanderlugt, C.J., and S.D. Miller. 2002. Epitope spreading in
immune-mediated diseases: implications for immunotherapy.
Nat. Rev. Immunol. 2:85–95.
8. Oldstone, M.B.A. 1998. Molecular mimicry and immune-
mediated diseases. FASEB J. 12:1255–1265.
9. London, C.A., M.P. Lodge, and A.K. Abbas. 2000. Func-
tional responses and costimulator dependence of memory
CD4  T cells. J. Immunol. 164:265–272.
10. Nicholson, L.B., H.-P. Waldner, A. Carrizosa, A. Sette, M.
Collins, and V.K. Kuchroo. 1998. Heteroclitic proliferative
responses and changes in cytokine profile induced by altered
peptides: implications for autoimmunity. Proc. Natl. Acad. Sci.
USA. 95:264–269.
11. Anderton, S.M., C.G. Radu, P.A. Lowrey, E.S. Ward, and
D.C. Wraith. 2001. Negative selection during the peripheral
immune response to antigen. J. Exp. Med. 193:1–11.
12. Nicholson, L.B., A.C. Anderson, and V.K. Kuchroo. 2000.
Tuning T cell activation threshold and effector function with
cross-reactive peptide ligands. Int. Immunol. 12:205–213.
13. Kedl, R.M., K.A. Rees, D.A. Hildeman, B. Schaefer, T.
Mitchell, J. Kappler, and P. Marrack. 2000. T cells compete
for access to antigen-bearing antigen-presenting cells. J. Exp.
Med. 192:1105–1113.
14. Anderson, A.C., H.-P. Waldner, V. Turchin, C. Jabs, M.
Prabhu Das, V.K. Kuchroo, and L.B. Nicholson. 2000. Au-
toantigen responsive T cell clones demonstrate unfocused
TCR cross-reactivity towards multiple related ligands: impli-
cations for autoimmunity. Cell. Immunol. 202:88–96.
15. Anderson, A.C., L.B. Nicholson, K.L. Legge, V. Turchin, H.
Zaghouani, and V.K. Kuchroo. 2000. High frequency of au-
toreactive myelin proteolipid protein-specific T cells in the
periphery of naive mice: Mechanisms of selection of the self-
reactive repertoire. J. Exp. Med. 191:761–770.
16. Li, W., C.D. Whaley, A. Mondino, and D.L. Mueller. 1996.
Blocked signal transduction to the ERK and JNK protein ki-
nases in anergic CD4  T cells. Science. 271:1272–1276.
17. Fields, P.E., T.F. Gajewski, and F.W. Fitch. 1996. Blocked
Ras activation in anergic CD4  T cells. Science. 271:1276–
1278.
18. Schwartz, R.H. 1996. Models of T cell anergy: is there a
common molecular mechanism. J. Exp. Med. 184:1–8.
19. Guse, A.H. 1998. Ca2  signaling in T-lymphocytes. Crit.
Rev. Immunol. 18:419–448.
20. June, C.H., and P.S. Rabinovitch. 1994. Intracellular ionized
calcium. Methods Cell Biol. 41:149–174.
21. Wange, R.L., and L.E. Samelson. 1996. Complex com-
plexes: signaling at the TCR. Immunity. 5:197–205.
22. Madrenas, J., R.H. Schwartz, and R.N. Germain. 1996. In-
terleukin 2 production, not the pattern of early T-cell anti-
gen receptor-dependent tyrosine phosphorylation, controls
anergy induction by both agonists and partial agonists. Proc.
Natl. Acad. Sci. USA. 93:9736–9741.
23. Sloan-Lancaster, J., A.S. Shaw, J.B. Rothbard, and P.M.
Allen. 1994. Partial T cell signaling: altered phospho-zeta and
lack of Zap70 recruitment in APL-induced T cell anergy.
Cell. 79:913–922.
24. van Oers, N.S., N. Killeen, and A. Weiss. 1994. ZAP-70 is
constitutively associated with tyrosine-phosphorylated TCR
zeta in murine thymocytes and lymph node T cells. Immu-
nity. 1:675–685.
25. Madrenas, J., R.L. Wange, J.L. Wang, N. Isakov, L.E.
Samelson, and R.N. Germain. 1995. Zeta phosphorylation
without ZAP-70 activation induced by TCR antagonists or
partial agonists. Science. 267:515–518.
26. Kersh, E.N., A.S. Shaw, and P.M. Allen. 1998. Fidelity of T
cell activation through multistep T cell receptor zeta phos-
phorylation. Science. 281:572–575.
27. Coffman, R.L., and S.L. Reiner. 1999. Immunology - in-
struction, selection, or tampering with the odds? Science. 284:
1283–1285.
28. Jenkins, M.K., and R.H. Schwartz. 1987. Antigen presenta-
tion by chemically modified splenocytes induces antigen-spe-
cific T cell unresponsiveness in vitro and in vivo. J. Exp.
Med. 165:302–319.
29. Sloan-Lancaster, J., B.D. Evavold, and P.M. Allen. 1993. In-
duction of T-cell anergy by altered T-cell-receptor ligand on
live antigen-presenting cells. Nature. 363:156–159.
30. Jenkins, M.K., C. Chen, G. Jung, D.L. Mueller, and R.H.
Schwartz. 1990. Inhibition of antigen-specific proliferation of
type 1 murine T cell clones after stimulation with immobi-
lized anti-CD3 monoclonal antibody. J. Immunol. 144:16–22.
31. Groux, H., M. Bigler, J.E. de Vries, and M.G. Roncarolo.
1996. Interleukin-10 induces a long-term antigen-specific
anergic state in human CD4  T cells. J. Exp. Med. 184:19–
29.
32. Migita, K., K. Eguchi, Y. Kawabe, T. Tsukada, Y. Ichinose,
S. Nagataki, and A. Ochi. 1995. Defective TCR-mediated
signaling in anergic T cells. J. Immunol. 155:5083–5087.
33. McKay, D.B., H.Y. Irie, G. Hollander, J.L. Ferrara, T.B.
Strom, Y. Li, and S.J. Burakoff. 1999. Antigen-induced un-
responsiveness results in altered T cell signaling. J. Immunol.
163:6455–6461.
34. Kimura, M., M. Yamashita, M. Kubo, M. Iwashima, C.
Shimizu, K. Tokoyoda, J. Chiba, M. Taniguchi, M. Kat-
sumata, and T. Nakayama. 2000. Impaired Ca/calcineurin
pathway in in vivo anergized CD4 T cells. Int. Immunol. 12:
817–824.
35. Blackman, M.A., T.H. Finkel, J. Kappler, J. Cambier, and P.
Marrack. 1991. Altered antigen receptor signaling in anergic
T cells from self-tolerant T-cell receptor beta-chain trans-
genic mice. Proc. Natl. Acad. Sci. USA. 88:6682–6686.
36. Utting, O., S.J. Teh, and H.S. Teh. 2000. A population of in
vivo anergized T cells with a lower activation threshold for
the induction of CD25 exhibit differential requirements in
mobilization of intracellular calcium and mitogen-activated
protein kinase activation. J. Immunol. 164:2881–2889.
37. Balamuth, F., D. Leitenberg, J. Unternaehrer, I. Mellman,
and K. Bottomly. 2001. Distinct patterns of membrane mi-
crodomain partitioning in Th1 and th2 cells. Immunity. 15:1162 T Cell Desensitization
729–738.
38. Scharenberg, A.M., and J.P. Kinet. 1998. PtdIns-3,4,5-P3: a
regulatory nexus between tyrosine kinases and sustained cal-
cium signals. Cell. 94:5–8.
39. Dolmetsch, R.E., R.S. Lewis, C.C. Goodnow, and J.I.
Healy. 1997. Differential activation of transcription factors
induced by Ca2  response amplitude and duration. Nature.
386:855–858.
40. Liu, K.Q., S.C. Bunnell, C.B. Gurniak, and L.J. Berg. 1998.
T cell receptor-initiated calcium release is uncoupled from
capacitative calcium entry in Itk-deficient T cells. J. Exp.
Med. 187:1721–1727.
41. Beverly, B., S.M. Kang, M.J. Lenardo, and R.H. Schwartz.
1992. Reversal of in vitro T cell clonal anergy by IL-2 stimu-
lation. Int. Immunol. 4:661–671.
42. Ryan, K.R., and B.D. Evavold. 1998. Persistence of peptide-
induced CD4  T cell anergy in vitro. J. Exp. Med. 187:89–
96.
43. Kawai, K., and P.S. Ohashi. 1995. Immunological function
of a defined T-cell population tolerized to low-affinity self
antigens. Nature. 374:68–69.
44. Davey, G.M., S.L. Schober, B.T. Endrizzi, A.K. Dutcher,
S.C. Jameson, and K.A. Hogquist. 1998. Preselection thy-
mocytes are more sensitive to T cell receptor stimulation
than mature T cells. J. Exp. Med. 188:1867–1874.
45. Lucas, B., I. Stefanova, K. Yasutomo, N. Dautigny, and
R.N. Germain. 1999. Divergent changes in the sensitivity of
maturing T cells to structurally related ligands underlies for-
mation of a useful T cell repertoire. Immunity. 10:367–376.
46. Girgis, L., M.M. Davis, and B.F. de St Groth. 1999. The
avidity spectrum of T cell receptor interactions accounts for
T cell anergy in a double transgenic model. J. Exp. Med. 189:
265–278.
47. Grossman, Z., and W.E. Paul. 1992. Adaptive cellular inter-
actions in the immune system: The tunable activation thresh-
old and the significance of subthreshold responses. Proc. Natl.
Acad. Sci. USA. 89:10365–10369.
48. Grossman, Z., and A. Singer. 1996. Tuning of activation
thresholds explains flexibility in the selection and develop-
ment of T cells in the thymus. Proc. Natl. Acad. Sci. USA. 93:
14747–14752.